Dr. Oyler is a Professor and Associate Program Director at the University of Chicago Internal Medicine Residency Program. She completed her undergraduate education at Stanford University and her medical degree and internal medicine residency and chief residency at the University of Chicago. She developed the University of Chicago Medicine’s Quality Improvement and Patient Safety Curriculum, a two year curriculum which has been used to teach over 500 Internal Medicine residents Practice-Based Learning and Improvement and Systems- Based Practice. She is currently co-director for the HealthCare Delivery Improvement Science Track at the U Chicago’s Pritzker, School of Medicine, and teaches quality improvement and patient safety nationally for the AAMC Teach for Quality program, the Society of Hospital Medicine’s Quality and Safety Educator Academy, and the American College of Physicians Advance QI program. Dr Oyler practices as a primary care provider on the south side of Chicago. She was Chair of the University of Chicago, Department of Medicine Women’s Committee from 2017 to 2024 and became the inaugural Chair of the BSD Women’s committee in 2024 after completing Executive Leadership in Healthcare (ELAM/ELH). She has led initiatives like increasing the presence of “Women on the Walls” and “Increasing Awards Given to Female Faculty in Academics”.
Twitter: @JOylerMD
Website: https://www.uchicagomedicine.org/find-a-physician/physician/julie-oyler
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 May 07.
PMID: 40334078
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw. 2025 05; 23(5):132-140.
PMID: 40340857
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. Front Immunol. 2025; 16:1558275.
PMID: 40264764
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review. Cancers (Basel). 2025 Apr 05; 17(7).
PMID: 40227780
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025 Mar 28; 15(1):47.
PMID: 40155599
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
PMID: 39699179
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia. 2025 Apr; 39(4):816-826.
PMID: 39910285
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025 Mar; 39(3):543-554.
PMID: 39870767
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma. Blood Neoplasia. 2025 Feb; 2(1):100065.
PMID: 40454405
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2024 Dec 19.
PMID: 39699179